SecBot SecBot
SECBOTREPLAY Home › Report › SGP

SGP · SpyGlass Pharma reported its Q4 and full-year 2025 financial results…

SpyGlass Pharma, Inc. · PRESS-RELEASE filed Mar 26, 2026 at 16:05 ET

At the news

BULLISHIMPACT 8/10

PRESS-RELEASE filed Mar 26, 2026 at 16:05 ET

SpyGlass Pharma reported its Q4 and full-year 2025 financial results alongside key clinical and corporate updates, including the successful $172.5 million IPO in February 2026. The company highlighted positive 12-month Phase 1/2 data for its BIM-IOL System, showing sustained intraocular pressure control and elimination of eye drops in 97% of patients. Despite increasing R&D and G&A expenses, the IPO has extended its cash runway to fund operations through 2028.

  • Raised $172.5 million in gross proceeds from IPO completed on February 9, 2026.
  • 12-month Phase 1/2 trial data show 98% of patients on the 78-mcg dose of BIM-IOL System were free of IOP-lowering eye drops, with a 34% mean IOP reduction and no serious ocular adverse events.
  • Cash, cash equivalents, and short-term investments totaled $107.4 million as of December 31, 2025, with post-IPO cash expected to fund operations through 2028.
  • Net loss was $12.6 million for Q4 2025 ($5.72/share), up from $8.4 million ($4.58/share) in Q4 2024.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access